BUFFALO, N.Y., Nov. 29, 2011 /PRNewswire/ -- Buffalo Heart Group, LLP, 2011: Today Dr. ZakiMasud, Kaleida Health, Buffalo, NY announced its first implant of the AngelMed Guardian cardiac monitor and alert system. The system is designed to reduce the time it takes patients to get to the emergency room during an impending heart attack. Dr. Hashmat Ashraf, performed the first implant in the state of New York, and is among the very first physicians across the United States to implant the experimental device.
(Photo: http://photos.prnewswire.com/prnh/20111129/NY13888 )
The AngelMed Guardian system is designed to track significant changes in the heart's electrical signal and then alert patients to seek medical attention. The objective of the ALERTS Pivotal Study is to provide an assessment of the safety and effectiveness of the AngelMed Guardian System.
David Garland, a 7th grade teacher at JFK in Buffalo, NY is the first patient in New York enrolled in the ALERTS study to receive the AngelMed Guardian System. David had a heart attack in July and underwent stent placement. He has a strong family history of heart disease; his symptoms included fatigue and "indigestion like" pain and had symptoms for weeks before his heart attack.
David Garland was successfully implanted with the device by Dr. Ashraf of Kaleida Health Millard Fillmore Gates Hospital.
Quote from Principal Investigator: "This study provides an excellent opportunity for some of our patients who are at high-risk of having another heart attack. The device is designed to measure changes in the electrical signal of the heart and alert the patient at the earliest onset of a heart attack so that they can get treatment as soon as possible."
According to the American Heart Association, one of every five deaths in the US is attributable to coronary heart disease. Furthermore, 50% of heart-attack fatalities occur within one hour of symptom onset and occur before the patient even reaches the hospital.
The AngelMed Guardian System is comprised of an internal implantable device about the size of a standard pacemaker with a lead into the heart, an external telemetry device, and a programmer that aids physicians in evaluating heart signals.
Buffalo Heart Group is among the first medical facilities to participate in the AngelMed Guardian system trial. To participate in the ALERTS study, patients must meet various inclusion criteria. For more information on the AngelMed Guardian system or the ALERTS study protocol, contact: Marcia Makoviecki of Angel Medical Systems @ (732) 542-5551 x205
Forward Looking Statements: Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company's products to patients, market and physician acceptance of the products, intellectual property protection and competitive product offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.
SOURCE Angel Medical Systems